Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter

Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr

Cenexi reports an EBITDA breakeven for the quarter

Roche’s Susvimo maintains vision over five years

Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint

Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally

Illumina launches new assay for tumor profiling

he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements

Sandoz to acquire Just–Evotec Biologics facility for $300 million

The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes

GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr

The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter